SUPN (SUPN) revenue breakdown
By product, Qelbree is the largest at 42% of fiscal 2025 revenue, growing 136% a year over 4 years.
Revenue by product
Fiscal years, as SUPN reports them in its 10-K filings; fiscal 2025 total $719M.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Qelbree | — | — | — | — | — | $10M | $61M | $140M | $241M | $305M | 42% |
| GOCOVRI | — | — | — | — | — | $10M | $104M | $120M | $131M | $147M | 20% |
| Collaboration revenue (ZURZUVAE) | — | — | — | — | — | — | — | — | — | $53M | 7% |
| APOKYN | — | — | — | — | $74M | $99M | $75M | $75M | $74M | $48M | 7% |
| Trokendi XR | — | — | — | — | $320M | $305M | $261M | $94M | $63M | $42M | 6% |
| Oxtellar XR | — | — | — | — | $99M | $111M | $115M | $113M | $99M | $41M | 6% |
| Royalty, licensing, and other revenues | $5M | $6M | $8M | $9M | $11M | $12M | $18M | $34M | $24M | $39M | 5% |
| Other | — | — | — | — | $17M | $33M | $32M | $31M | $29M | $27M | 4% |
| ONAPGO | — | — | — | — | — | — | — | — | — | $17M | 2% |
| Net product sales | — | — | $400M | $383M | — | — | — | — | — | — | — |
| Trokendi Xr | — | $227M | — | — | — | — | — | — | — | — | — |
| Product | $210M | — | — | — | — | — | — | — | — | — | — |
| Oxtellar XR | — | $68M | — | — | — | — | — | — | — | — | — |
| Licensing revenue | — | $2M | — | — | — | — | — | — | — | — | — |
| Licensing revenue | — | — | $750,000 | — | — | — | — | — | — | — | — |
| Licensing | $239,000 | — | — | — | — | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for SUPN.
Open SUPN in InvestinglyQuestions
Where does SUPN make its money?
In fiscal 2025, by product: Qelbree $305M, GOCOVRI $147M, Collaboration revenue (ZURZUVAE) $53M, APOKYN $48M, Trokendi XR $42M.
From SUPN's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.